Matrix Capital leads $195 mln round for Adaptive Biotechnologies
Seattle-based Adaptive Biotechnologies, a provider of immunosequencing diagnostics, has raised $195 million in funding, the company announced in a statement.
7 May 2015•1 min read
Seattle-based Adaptive Biotechnologies, a provider of immunosequencing diagnostics, has raised $195 million in funding, the company announced in a statement.
